Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Headlines > Lilly sues four compounders over copies of weight-loss drugs
    Headlines

    Lilly sues four compounders over copies of weight-loss drugs

    Published by Global Banking & Finance Review®

    Posted on April 23, 2025

    2 min read

    Last updated: January 24, 2026

    Lilly sues four compounders over copies of weight-loss drugs - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Eli Lilly sues four compounders for selling unapproved tirzepatide products after a judge blocked pharmacy copies of its drugs.

    Lilly Takes Legal Action Against Compounders Over Drug Copies

    (Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines.

    Compounders were, until recently, allowed to produce copies of obesity drugs while the FDA classified them as being in shortage, under U.S. rules that permit such manufacturing only during supply gaps.

    Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including the blockbuster, Mounjaro.

    Lilly's lawsuits, to be filed in California, name Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds, accusing them of selling tirzepatide knockoffs — including versions with additives or in oral form — without clinical evidence of safety or effectiveness.

    Indianapolis-based Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide.

    Earlier this month, the company sued two other compounders and said it would send about fifty cease and desist letters, asking companies to confirm that they have already ceased mass compounding.

    Compounding facilities create medicines by combining, mixing or altering drug ingredients.

    (Reporting by Christy Santhosh in Bengaluru; Editing by Nivedita Bhattacharjee)

    Key Takeaways

    • •Eli Lilly sues four compounders for selling unapproved tirzepatide products.
    • •A U.S. judge blocked pharmacies from making copies of Lilly's drugs.
    • •Compounders were previously allowed to produce copies during shortages.
    • •Lilly's lawsuits target Mochi Health, Fella Health, Willow Health, and Henry Meds.
    • •The lawsuits claim the products lack clinical evidence of safety or effectiveness.

    Frequently Asked Questions about Lilly sues four compounders over copies of weight-loss drugs

    1What is the main topic?

    The main topic is Eli Lilly's lawsuits against compounders selling unapproved tirzepatide products.

    2Why did Lilly sue the compounders?

    Lilly sued them for selling unapproved copies of its weight-loss and diabetes drugs.

    3What is tirzepatide?

    Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including Mounjaro.

    More from Headlines

    Explore more articles in the Headlines category

    Image for Two airports in Poland closed due to Russian strikes on Ukraine
    Two airports in Poland closed due to Russian strikes on Ukraine
    Image for Exclusive-US plans initial payment towards billions owed to UN-envoy Waltz
    Exclusive-US plans initial payment towards billions owed to UN-envoy Waltz
    Image for Trump says good talks ongoing on Ukraine
    Trump says good talks ongoing on Ukraine
    Image for France to rally aid for Lebanon as it warns truce gains remain fragile
    France to rally aid for Lebanon as it warns truce gains remain fragile
    Image for Exclusive-US aims for March peace deal in Ukraine, quick elections, sources say
    Exclusive-US aims for March peace deal in Ukraine, quick elections, sources say
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Olympics-Italy's president takes the tram in video tribute to Milan transport
    Olympics-Italy's president takes the tram in video tribute to Milan transport
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for Exclusive-Bangladesh PM front-runner rejects unity government offer, says his party set to win
    Exclusive-Bangladesh PM front-runner rejects unity government offer, says his party set to win
    Image for Azerbaijan issues strong protest to Russia over lawmaker's comments on Karabakh trial
    Azerbaijan issues strong protest to Russia over lawmaker's comments on Karabakh trial
    View All Headlines Posts
    Previous Headlines PostECB expects wage growth to ease considerably this year
    Next Headlines PostForget the film: Vatican is preparing for the real 'Conclave'